Medicine guide

Naproxen Aurobindo EC 250 mg

As listed in the register: Naproxen Aurobindo EC 250 mg, maagsapresistente tabletten

250 mg · maagsapresistente tablet

  • Prescription only
  • Muscles, joints and bones
Active substance
Naproxen
Made by
Aurobindo Pharma B.V.

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Medicine groupMuscles, joints and bonesM01AE02

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

How it works

This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (naproxen). It describes the substance, not this Bulgarian product — its uses and doses can differ.

Naproxen has analgesic, anti-inflammatory, and antipyretic properties.

Naproxen sodium has been developed as a more rapidly absorbed formulation of naproxen for use as an analgesic.

Half-life12–17 h
Mostly cleared after≈ 3 daysfive half-lives — our arithmetic
How the body breaks it down

Naproxen is extensively metabolized in the liver to 6-0-desmethyl naproxen, and both parent and metabolites do not induce metabolizing enzymes.

How it leaves the body

Approximately 95% of the naproxen from any dose is excreted in the urine, primarily as naproxen (<1%), 6-0-desmethyl naproxen (<1%) or their conjugates (66% to 92%).

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-05-19

Safety of the active substance

This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (naproxen). It describes the substance, not this Bulgarian product — its uses and doses can differ.

Serious warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events.

Must not be used by
  • Naproxen tablets and naproxen sodium tablets are contraindicated in the following patients:.
  • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [ see Warnings and Precautions ( 5.7, 5.9 ) ].
  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
  • Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [ see Warnings and Precautions ( 5.7, 5.8 ) ].
Most common side effects

Most common adverse reactions to naproxen were dyspepsia, abdominal pain, nausea, headache, rash, ecchymosis, and edema.

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

BulgariaNo exact match for this strength and form

SpainNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byAurobindo Pharma B.V.
Active substanceNaproxen
Used inMuscles, joints and bones
Strength250 mg
Formmaagsapresistente tablet
ClassificationM01AE02 · Muscles, joints and bones
Routeoraal gebruik
Dispensing (as stated by the register)Uitsluitend recept
Name in the registerNaproxen Aurobindo EC 250 mg, maagsapresistente tabletten
RVG21931

Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician

Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.